Bacteria-Targeting Nanoparticles with ROS-Responsive Antibiotic Release to Eradicate Biofilms and Drug-Resistant Bacteria in Endophthalmitis
Jian Yu,Huan Xu,Jiaojiao Wei,Liangliang Niu,Haohao Zhu,Chunhui Jiang
DOI: https://doi.org/10.2147/ijn.s433919
IF: 7.033
2024-03-20
International Journal of Nanomedicine
Abstract:Jian Yu, 1, 2, &ast Huan Xu, 1, 2, &ast Jiaojiao Wei, 1, 2 Liangliang Niu, 1, 2 Haohao Zhu, 1, 3 Chunhui Jiang 1, 2 1 Department of Ophthalmology and Visual Science, Eye, Ear, Nose and Throat Hospital, Shanghai Medical College of Fudan University, Shanghai, People's Republic of China; 2 Key Laboratory of Myopia of State Health Ministry and Key Laboratory of Visual Impairment and Restoration of Shanghai, Shanghai, People's Republic of China; 3 Department of Ophthalmology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chunhui Jiang, Department of Ophthalmology and Vision Science, Eye and ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, People's Republic of China, Email Haohao Zhu, Department of Ophthalmology, Shanghai Fifth People's Hospital, Fudan University, 128 Ruili Road, Shanghai, 200240, People's Republic of China, Tel +86-21-64308151, Fax +86-21-64300477, Email Background: Bacterial endophthalmitis is an acute progressive visual threatening disease and one of the most important causes of blindness worldwide. Current treatments are unsatisfactory due to the emergence of drug-resistant bacteria and the formation of biofilm. Purpose: The aim of our research was to construct a novel nano-delivery system with better antimicrobial and antibiofilm effects. Methods: This study developed a novel antibiotic nanoparticle delivery system (MXF@UiO-UBI-PEGTK), which is composed of (i) moxifloxacin (MXF)-loaded UiO-66 nanoparticle as the core, (ii) bacteria-targeting peptide ubiquicidin (UBI 29-41 ) immobilized on UiO-66, and (iii) ROS-responsive poly (ethylene glycol)-thioketal (PEG-TK) as the surface shell. Then the important properties of the newly developed delivery system, including biocompatibility, toxicity, release percentage, thermal stability, ability of targeting bacteria, and synergistic antibacterial effects on bacterial biofilms and endophthalmitis, were evaluated. Results: In vitro, MXF@UiO-UBI-PEGTK exhibited significant antibiotic effects including the excellent antibiofilm property against Staphylococcus aureus, Pseudomonas aeruginosa , and methicillin-resistant Staphylococcus aureus at high levels of ROS. Moreover, MXF@UiO-UBI-PEGTK demonstrated outstanding efficacy in treating bacterial endophthalmitis in vivo. Conclusion: This novel nanoparticle delivery system with ROS-responsive and bacteria-targeted properties promotes the precise and effective release of drugs and has significant potential for clinical application of treating bacterial endophthalmitis. Keywords: endophthalmitis, nanoparticles, bacterial biofilms, ROS-responsive, moxifloxacin Graphical Endophthalmitis, which is a severe inflammation of intraocular fluids (vitreous and aqueous) and tissues, generally leads to total loss of vision or atrophy of the eyeball. The most prevalent causes of endophthalmitis are intraocular surgery, trauma, and endogenous infection. 1 Furthermore, the most common microorganism that causes such inflammation is bacteria. 2 Currently, bacterial endophthalmitis is generally treated with an intravitreal injection of antibiotics with or without vitrectomy. 3 Despite these efforts and the development of new antibiotics, most patients with bacterial endophthalmitis have a very poor visual prognosis (20/400 or worse). 2 The main reasons for these unfavorable results include the formation of biofilms and the emergence of drug-resistant bacteria. 4,5 Bacterial biofilms are a type of membrane formed by bacteria and constitute encysted complexes secreted by bacteria after adsorption onto active or inactive surfaces, including polysaccharide matrix, fibronectin, lipoprotein, and other polysaccharide proteins. 6 By decreasing the permeability of antibiotics, bacterial biofilms significantly increase the pathogenicity and drug resistance of bacteria. 7 To address the issue of biofilm formation, several strategies have been applied, including chemotherapy, such as those using new antibiotics, and non-chemotherapy, such as those involving targeted antibacterial systems. 8–10 Ideal intravitreal antibiotics should exhibit low toxicity and broad-spectrum antibacterial properties. Moxifloxacin (MXF) is a fourth-generation quinolone that inhibits deoxyribonucleic acid (DNA) gyrase and topoisomerase in microorganisms and exhibits satisfactory antibacterial activity against both gram -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology